ALA-3000 vs Zelquistinel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline

ALA-3000

Developed by Alar Pharmaceuticals

Phase 1 in Major Depressive Disordersmall molecule
Partial signal

NCT06965569 · Phase 1 · completed

This randomized, double-blind, placebo-controlled multiple-dose study gave subcutaneous ALA-3000 or placebo, with a standard oral antidepressant, to patients with treatment-resistant depression. All of its primary measures were safety and tolerability measures, which have no formal efficacy test, so there is no met or missed result. The company reports that side effects were mild to moderate and that no dissociation, sedation or psychosis-like symptoms were seen. Effects on depression scores were exploratory. The figures come from the company's press release.

Reported efficacy

Incidence of treatment-related adverse events (AEs) (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal orthostatic blood pressure (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal heart rate (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal blood oxygen saturation (pulse oximetry) (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal respiratory rate (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal body temperature (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal 12-lead electrocardiogram (ECG) parameters (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal hematologic findings (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal serum chemistry test result (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal urine test result (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal urine cytologic findings (Baseline (prior to dosing) and the End of Study (Day 36) visit); Incidence and severity of dissociative symptoms assessed by Clinician Administered Dissociative States Scale (CADSS) (Baseline (prior to dosing) through the End of Study (Day 36)); Incidence and severity of treatment-emergent sedation assessed by Modified Observer's Assessment of Alertness/ Sedation (MOAA/S) (Baseline (prior to dosing) through the End of Study (Day 36)); Incidence and severity of potential withdrawal symptoms assessed by Physician Withdrawal Checklist; 20-item (PWC-20) (Two weeks after last investigational product administration and through the End of Study (Day 36)/Early termination or Follow up visit); Incidence and severity of suicide ideation assessed by Columbia Suicide Severity Rating Scale (C-SSRS) (Baseline (prior to dosing) and through the End of Study (Day 36)/Early termination or Follow up visit); Incidence and severity of four-item positive symptom subscale of the Brief Psychiatric Rating Scale (BPRS+) (Baseline (prior to dosing) and through the End of Study (Day 36)/Early termination); Injection site tolerability based on injection site grading scale (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit); Injection site tolerability based on injection site pain visual analog scale (VAS) (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit); Injection site tolerability based on injection site evaluation for potential reactions and evidence of removal (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit): Primary, safety and tolerability (no formal efficacy test): treatment-related adverse events were mild to moderate in severity, and no dissociation, sedation or psychosis-like symptoms were observed. (not_applicable)

Result source: NCT06965569

Zelquistinel

Developed by Syndeio Biosciences

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT03726658 · Phase 1/2 · completed

The study randomized 226 participants overall to several zelquistinel dose groups or placebo and masked both participants and investigators, but it stated that no power calculation was performed and each comparison was relatively small. The primary MADRS comparisons were clinical measures but were missed, with all reported p-values above 0.05, so the findings provide limited evidence of benefit.

Next expected readout: September 2027 · NCT06547489 (registry estimate)

Reported efficacy

Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group (Baseline (Day1) to Day 2); Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose) (Baseline (Day 1) to Day 8): Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group (Baseline (Day1) to Day 2): AGN-241751 3mg Daily -9.4 score on a scale (Standard Error 1.57) | AGN-241751 10mg Daily -6.7 score on a scale (Standard Error 1.58) | AGN-241751 25mg Daily -9.5 score on a scale (Standard Error 1.57) vs Placebo Daily -9.3 score on a scale (Standard Error 1.61) (missed)

Result source: NCT03726658

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointALA-3000Zelquistinel
MADRS, change (acute)—Not reported-10.5 vs -10.9+0.4 vs placebo25mg Two Times Per Day · wk 1 · n 38NCT03726658
25 other results
  • -9.5 vs -9.3 25mg Daily · wk 0.142857 · n 26 · Phase 1/2 · primary NCT03726658
  • -6.7 vs -9.3 10mg Daily · wk 0.142857 · n 26 · Phase 1/2 · primary NCT03726658
  • -12.8 vs -10.9 3mg Two Times Per Day · wk 1 · n 37 · Phase 1/2 · primary NCT03726658
  • -9.4 vs -9.3 3mg Daily · wk 0.142857 · n 26 · Phase 1/2 · primary NCT03726658
  • -14.5 vs -13.6 25mg Daily · wk 3.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -16.5 vs -16.5 25mg Two Times Per Day · wk 3 · n 38 · Phase 1/2 · secondary NCT03726658
  • -15 vs -16.9 25mg Two Times Per Day · wk 2.57 · n 38 · Phase 1/2 · secondary NCT03726658
  • -13.2 vs -11.6 25mg Daily · wk 2.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -15.3 vs -14.7 25mg Two Times Per Day · wk 2 · n 38 · Phase 1/2 · secondary NCT03726658
  • -15.2 vs -14 25mg Two Times Per Day · wk 1.57 · n 38 · Phase 1/2 · secondary NCT03726658
  • -14.1 vs -12 25mg Daily · wk 1.29 · n 26 · Phase 1/2 · secondary NCT03726658
  • -11.8 vs -13.6 10mg Daily · wk 3.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -13.7 vs -11.6 10mg Daily · wk 2.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -13.6 vs -12 10mg Daily · wk 1.29 · n 26 · Phase 1/2 · secondary NCT03726658
  • -12.5 vs -13.6 3mg Daily · wk 3.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -17.3 vs -16.5 3mg Two Times Per Day · wk 3 · n 37 · Phase 1/2 · secondary NCT03726658
  • -18.3 vs -16.9 3mg Two Times Per Day · wk 2.57 · n 37 · Phase 1/2 · secondary NCT03726658
  • -13.2 vs -11.6 3mg Daily · wk 2.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -17 vs -14.7 3mg Two Times Per Day · wk 2 · n 37 · Phase 1/2 · secondary NCT03726658
  • -15.8 vs -14 3mg Two Times Per Day · wk 1.57 · n 37 · Phase 1/2 · secondary NCT03726658
  • -13 vs -12 3mg Daily · wk 1.29 · n 26 · Phase 1/2 · secondary NCT03726658
  • -11.5 vs -13.6 wk 3 · n 48 · Phase 2 · secondary NCT03586427
  • -12.5 vs -13.6 wk 3 · n 50 · Phase 2 · secondary NCT03586427
  • -14.1 vs -13.6 wk 3 · n 52 · Phase 2 · secondary NCT03586427
  • -13.5 vs -13.6 wk 3 · n 50 · Phase 2 · secondary NCT03586427
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported—Not reported
MADRS remission—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

ALA-3000
—Not reported
Zelquistinel
-10.5 vs -10.9+0.4 vs placebo25mg Two Times Per Day · wk 1 · n 38NCT03726658
25 other results
  • -9.5 vs -9.3 25mg Daily · wk 0.142857 · n 26 · Phase 1/2 · primary NCT03726658
  • -6.7 vs -9.3 10mg Daily · wk 0.142857 · n 26 · Phase 1/2 · primary NCT03726658
  • -12.8 vs -10.9 3mg Two Times Per Day · wk 1 · n 37 · Phase 1/2 · primary NCT03726658
  • -9.4 vs -9.3 3mg Daily · wk 0.142857 · n 26 · Phase 1/2 · primary NCT03726658
  • -14.5 vs -13.6 25mg Daily · wk 3.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -16.5 vs -16.5 25mg Two Times Per Day · wk 3 · n 38 · Phase 1/2 · secondary NCT03726658
  • -15 vs -16.9 25mg Two Times Per Day · wk 2.57 · n 38 · Phase 1/2 · secondary NCT03726658
  • -13.2 vs -11.6 25mg Daily · wk 2.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -15.3 vs -14.7 25mg Two Times Per Day · wk 2 · n 38 · Phase 1/2 · secondary NCT03726658
  • -15.2 vs -14 25mg Two Times Per Day · wk 1.57 · n 38 · Phase 1/2 · secondary NCT03726658
  • -14.1 vs -12 25mg Daily · wk 1.29 · n 26 · Phase 1/2 · secondary NCT03726658
  • -11.8 vs -13.6 10mg Daily · wk 3.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -13.7 vs -11.6 10mg Daily · wk 2.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -13.6 vs -12 10mg Daily · wk 1.29 · n 26 · Phase 1/2 · secondary NCT03726658
  • -12.5 vs -13.6 3mg Daily · wk 3.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -17.3 vs -16.5 3mg Two Times Per Day · wk 3 · n 37 · Phase 1/2 · secondary NCT03726658
  • -18.3 vs -16.9 3mg Two Times Per Day · wk 2.57 · n 37 · Phase 1/2 · secondary NCT03726658
  • -13.2 vs -11.6 3mg Daily · wk 2.14 · n 26 · Phase 1/2 · secondary NCT03726658
  • -17 vs -14.7 3mg Two Times Per Day · wk 2 · n 37 · Phase 1/2 · secondary NCT03726658
  • -15.8 vs -14 3mg Two Times Per Day · wk 1.57 · n 37 · Phase 1/2 · secondary NCT03726658
  • -13 vs -12 3mg Daily · wk 1.29 · n 26 · Phase 1/2 · secondary NCT03726658
  • -11.5 vs -13.6 wk 3 · n 48 · Phase 2 · secondary NCT03586427
  • -12.5 vs -13.6 wk 3 · n 50 · Phase 2 · secondary NCT03586427
  • -14.1 vs -13.6 wk 3 · n 52 · Phase 2 · secondary NCT03586427
  • -13.5 vs -13.6 wk 3 · n 50 · Phase 2 · secondary NCT03586427

CGI-S, change (acute)

ALA-3000
—Not reported
Zelquistinel
—Not reported

MADRS response

ALA-3000
—Not reported
Zelquistinel
—Not reported

MADRS remission

ALA-3000
—Not reported
Zelquistinel
—Not reported

Relapse (% of patients)

ALA-3000
—Not reported
Zelquistinel
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ALA-3000: no structured comparison results are available for Major Depressive Disorder.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ALA-3000: 0 of 4 rows · Zelquistinel: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricZelquistinel
Dropout rate
7.7%25mg Dailya
NCT03726658 · Phase 1/2 · monotherapy
show 8 more results
12.5%25mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
0%10mg Daily
NCT03726658 · Phase 1/2 · monotherapy
3.8%3mg Daily
NCT03726658 · Phase 1/2 · monotherapy
15%3mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
0%AGN-241751 Dose 1
NCT03586427 · Phase 2 · registry result, not featured evidence
8%AGN-241751 Dose 2
NCT03586427 · Phase 2 · registry result, not featured evidence
11.5%AGN-241751 Dose 3
NCT03586427 · Phase 2 · registry result, not featured evidence
8%AGN-241751 Dose 4
NCT03586427 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—25mg Dailya
NCT03726658 · Phase 1/2 · monotherapy
show 8 more results
—25mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
—10mg Daily
NCT03726658 · Phase 1/2 · monotherapy
—3mg Daily
NCT03726658 · Phase 1/2 · monotherapy
—3mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
0%AGN-241751 Dose 1
NCT03586427 · Phase 2 · registry result, not featured evidence
0%AGN-241751 Dose 2
NCT03586427 · Phase 2 · registry result, not featured evidence
1.9%AGN-241751 Dose 3
NCT03586427 · Phase 2 · registry result, not featured evidence
0%AGN-241751 Dose 4
NCT03586427 · Phase 2 · registry result, not featured evidence
Serious AEs
0%25mg Dailya
NCT03726658 · Phase 1/2 · monotherapy
show 8 more results
0%25mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
0%10mg Daily
NCT03726658 · Phase 1/2 · monotherapy
0%3mg Daily
NCT03726658 · Phase 1/2 · monotherapy
0%3mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
0%AGN-241751 Dose 1
NCT03586427 · Phase 2 · registry result, not featured evidence
0%AGN-241751 Dose 2
NCT03586427 · Phase 2 · registry result, not featured evidence
0%AGN-241751 Dose 3
NCT03586427 · Phase 2 · registry result, not featured evidence
0%AGN-241751 Dose 4
NCT03586427 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
25mg Dailya
headache 15.4% (placebo 34.1%)
nausea 7.7% (placebo 4.9%)
abnormal dreams 0% (placebo 4.9%)
NCT03726658 · Phase 1/2 · monotherapy
show 8 more results
25mg Two Times Per Day
headache 24.4% (placebo 34.1%)
nausea 14.6% (placebo 4.9%)
abnormal dreams 4.9% (placebo 4.9%)
NCT03726658 · Phase 1/2 · monotherapy
10mg Daily
headache 19.2% (placebo 34.1%)
nausea 11.5% (placebo 4.9%)
abnormal dreams 0% (placebo 4.9%)
NCT03726658 · Phase 1/2 · monotherapy
3mg Daily
headache 15.4% (placebo 34.1%)
nausea 7.7% (placebo 4.9%)
abnormal dreams 0% (placebo 4.9%)
NCT03726658 · Phase 1/2 · monotherapy
3mg Two Times Per Day
headache 14.6% (placebo 34.1%)
abnormal dreams 7.3% (placebo 4.9%)
back pain 7.3% (placebo 2.4%)
NCT03726658 · Phase 1/2 · monotherapy
headache 6.3% (placebo 7.8%)
diarrhea 4.2% (placebo 0%)
dizziness 4.2% (placebo 3.9%)
NCT03586427 · Phase 2 · registry result, not featured evidence
insomnia 10% (placebo 2%)
headache 6% (placebo 7.8%)
nausea 6% (placebo 3.9%)
NCT03586427 · Phase 2 · registry result, not featured evidence
anxiety 5.8% (placebo 0%)
dizziness 5.8% (placebo 3.9%)
headache 5.8% (placebo 7.8%)
NCT03586427 · Phase 2 · registry result, not featured evidence
dizziness 6% (placebo 3.9%)
dry mouth 6% (placebo 2%)
abnormal dreams 4% (placebo 0%)
NCT03586427 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Zelquistinel

MADRS -9.5 vs -9.3 placebo score @ 0.142857wk25mg Daily
absolute change · score
NCT03726658 · Phase 1/2 · monotherapy
show 29 more results
-10.5 vs -10.9 placebo score @ 1wk25mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
-14.1 vs -12 placebo score @ 1.29wk25mg Daily
NCT03726658 · Phase 1/2 · monotherapy
-13.2 vs -11.6 placebo score @ 2.14wk25mg Daily
NCT03726658 · Phase 1/2 · monotherapy
-14.5 vs -13.6 placebo score @ 3.14wk25mg Daily
NCT03726658 · Phase 1/2 · monotherapy
-15.2 vs -14 placebo score @ 1.57wk25mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
-15.3 vs -14.7 placebo score @ 2wk25mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
-15 vs -16.9 placebo score @ 2.57wk25mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
-16.5 vs -16.5 placebo score @ 3wk25mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
-6.7 vs -9.3 placebo score @ 0.142857wk10mg Daily
NCT03726658 · Phase 1/2 · monotherapy
-13.6 vs -12 placebo score @ 1.29wk10mg Daily
NCT03726658 · Phase 1/2 · monotherapy
-13.7 vs -11.6 placebo score @ 2.14wk10mg Daily
NCT03726658 · Phase 1/2 · monotherapy
-11.8 vs -13.6 placebo score @ 3.14wk10mg Daily
NCT03726658 · Phase 1/2 · monotherapy
-9.4 vs -9.3 placebo score @ 0.142857wk3mg Daily
NCT03726658 · Phase 1/2 · monotherapy
-12.8 vs -10.9 placebo score @ 1wk3mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
-13 vs -12 placebo score @ 1.29wk3mg Daily
NCT03726658 · Phase 1/2 · monotherapy
-13.2 vs -11.6 placebo score @ 2.14wk3mg Daily
NCT03726658 · Phase 1/2 · monotherapy
-12.5 vs -13.6 placebo score @ 3.14wk3mg Daily
NCT03726658 · Phase 1/2 · monotherapy
-15.8 vs -14 placebo score @ 1.57wk3mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
-17 vs -14.7 placebo score @ 2wk3mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
-18.3 vs -16.9 placebo score @ 2.57wk3mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
-17.3 vs -16.5 placebo score @ 3wk3mg Two Times Per Day
NCT03726658 · Phase 1/2 · monotherapy
-8.6 vs -7.7 placebo score
NCT03586427 · Phase 2 · registry result, not featured evidence
-8 vs -7.7 placebo score
NCT03586427 · Phase 2 · registry result, not featured evidence
-9.5 vs -7.7 placebo score
NCT03586427 · Phase 2 · registry result, not featured evidence
-10.6 vs -7.7 placebo score
NCT03586427 · Phase 2 · registry result, not featured evidence
-11.5 vs -13.6 placebo score @ 3wk
NCT03586427 · Phase 2 · registry result, not featured evidence
-12.5 vs -13.6 placebo score @ 3wk
NCT03586427 · Phase 2 · registry result, not featured evidence
-14.1 vs -13.6 placebo score @ 3wk
NCT03586427 · Phase 2 · registry result, not featured evidence
-13.5 vs -13.6 placebo score @ 3wk
NCT03586427 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALA-3000's landscape · Zelquistinel's landscape